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Advanced Breast Cancer (ABC) comprises both locally advanced
breast cancer (LABC) and metastatic breast cancer (MBC) [1].
Although treatable, MBC remains virtually an incurable disease
with a median overall survival (OS) of3 years and a 5-year sur-
vival of only 25% [2, 3]. The MBC Decade Report [2] shows
that progress has been slow in terms of improved outcomes, qual-
ity of life (QoL), awareness and information regarding ABC.
More recently, some studies seem to indicate an improvement in
OS, mostly due to advances in human epidermal growth factor
receptor 2 (HER2)-positive ABC [4–6]. The better survival is
seen in an environment with access to the best available care and
particularly in de novo ABC, while recurrent ABC seems to be-
come harder to manage [7, 8].
The last decade has seen an improvement in the levels of evi-
dence (LoEs) used for many of the ABC recommendations, how-
ever, still far from the LoEs existing for the majority of early
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breast cancer guidelines. More and better, more innovatively
designed trials are urgently needed, in particular to address clinic-
ally important questions, not necessarily related to a specific
therapeutic agent. The use of real world evidence and the applica-
tion of big data analysis to oncology may soon become important
additional pathways to acquire the necessary LoEs.
At the research level, efforts continue to better understand the
biology and heterogeneity of ABC, as well as mechanisms of tu-
mour resistance and biomarkers predictive of response to the dif-
ferent therapeutic options. However, the majority of the recent
research highlights are not yet ready for routine clinical practice
implementation.
The 4th International Consensus Conference for ABC (ABC 4)
took place in Lisbon, Portugal on 2–4 November 2017, bringing
together 1300 participants from 88 countries, including health
professionals, patient advocates and journalists. Its primary aim
is the development of international consensus guidelines for the
management of ABC patients. These guidelines are based on the
most up-to-date evidence and can be used to guide treatment de-
cision making in many different healthcare settings globally, with
the necessary adaptations due to different access to care.
The ABC guidelines are developed as a joint effort from ESO
and ESMO and are endorsed by EUSOMA (European Society of
Breast Cancer Specialists), ESTRO (European Society of
Radiation Oncology), UICC (Union for International Cancer
Control), SIS (Senologic International Society) and Flam
(Federatio´nLatinoAmericana de Mastologia). There was also offi-
cial representation of ASCO (American Society of Clinical
Oncology) in the consensus panel. The ABC 4 Conference was also
organised under the auspices of OECI (Organization of European
Cancer Institutes) and with the support of the BCRF (Breast Cancer
Research Foundation) and the Susan G Komen for the Cure.
The present manuscript summarises the guidelines developed at
ABC 4 and is supported with the LoEs, grades of recommendation
(GoRs), percentages of consensus reached at the Conference and
supporting references. In addition, the ESMO Magnitude of Clinical
Benefit Scale (ESMO-MCBS) was applied to new European
Medicines Agency (EMA)-approved drugs [9], and ESMO-MCBS
scores for new therapies/indications are included. ESMO-MCBS
version 1.1 (v1.1) [9] was used to calculate scores for new therapies/
indications approved by the EMA since 1 January 2016.
Methodology
Before the ABC 4 Conference, a set of preliminary recommenda-
tion statements on the management of ABC were prepared, based
on available published data and following the ESMO guidelines
methodology. These recommendations were circulated to all 42
panel members by email for comments and corrections on con-
tent and wording. A final set of recommendations was presented,
discussed and voted upon during the consensus session of ABC 4.
All panel members were instructed to vote on all questions, with
members with a potential conflict of interest or who did not feel
comfortable answering the question (e.g. due to lack of expertise
in a particular field) instructed to vote ‘abstain’. A new possible
answer was included in the Precision Medicine statements:
‘Insufficient data’, which should be selected if the panel member
believes the existent data were not enough to vote ‘yes’ or ‘no’,
highlighting an area where research is needed. Additional changes
in the wording of statements were made during the session.
The statements related to management of side effects and diffi-
cult symptoms, included under the Supportive and Palliative Care
section, were not voted on during the consensus session, but dis-
cussed and unanimously agreed by email, and are considered to
have 100% agreement. Previous ABC recommendations that did
not require update or only minor changes were not re-voted but
were reviewed by all panel members by email and remain valid. To
provide a full overview of all ABC guidelines currently approved,
the authors have listed all recommendations per subject, high-
lighting those that were discussed, voted and approved in ABC 4.
Supplementary Table S1, available at Annals of Oncology on-
line, describes the new grading system used, as per ESMO guide-
lines methodology, adapted from [10]; see http://www.esmo.org/
Guidelines/ESMO-Guidelines-Methodology.
Supplementary Table S2, available at Annals of Oncology on-
line, lists all members of the ABC 4 consensus panel and their dis-
closures of any relationships with the pharmaceutical industry
that could be perceived as a potential conflict of interest.
Supplementary Figures, available at Annals of Oncology online,
features updated ABC diagnostic and treatment algorithms.
Slides with all ABC guidelines statements are available online at
http://www.abc-lisbon.org/ and http://oncologypro.esmo.org/
Guidelines/ESMO-Consensus-Conferences/Breast-Cancer.
Section I: ABC definitions
Guideline statement LoE/GoR Consensus
Visceral crisis is deﬁned as severe organ
dysfunction as assessed by signs and
symptoms, laboratory studies and rapid
progression of disease. Visceral crisis is
not the mere presence of visceral meta-
stases but implies important visceral
compromise leading to a clinical indica-
tion for a more rapidly efﬁcacious ther-
apy, particularly since another treatment
option at progression will probably not
be possible.
Expert opinion/
n/a
95%
Primary endocrine resistance is deﬁned
as relapse while on the ﬁrst 2 years of
adjuvant ET, or PD within ﬁrst 6 months
of ﬁrst-line ET for ABC, while on ET.
Expert opinion/
n/a
67%
Secondary endocrine resistance is
deﬁned as relapse while on adjuvant ET
but after the ﬁrst 2 years, or relapse with-
in 12 months of completing adjuvant
ET, or PD  6 months after initiating ET
for ABC, while on ET.
Expert opinion/
n/a
67%
Oligometastatic disease is deﬁned as
low volume metastatic disease with lim-
ited number and size of metastatic
lesions (up to 5 and not necessarily in
Expert opinion/
n/a
78%
Continued
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Following the effort to standardise definitions and homogenise
the use of certain medical terms, ABC 4 provides three additional
definitions.
Adequate ovarian function suppression (OFS) or ablation
(OFA) is a somewhat controversial but crucial issue in the treat-
ment of pre-menopausal patients with oestrogen receptor
(ER)-positive ABC. As already extensively discussed in previous
editions, the main recommendation for these patients is the induc-
tion of OFS/OFA, to which an additional endocrine agent should
be added [1, 11]. The method for inducing OFS or OFA may vary
due to patient’s preferences, logistical and financial issues. Bilateral
salpingo-oophorectomy by a minimal invasive approach is a rea-
sonable option and should be discussed with patients. The con-
firmation that ovarian function is adequately suppressed when
chemically induced [i.e. luteinising hormone-releasing hormone
(LHRH) agonist] is not always straightforward but it is indispens-
able if an aromatase inhibitor (AI) is given concomitantly, in view
of the oestrogen-inducing effect of these agents in the absence of
OFS. The best way to obtain this confirmation [i.e. testing oestra-
diol levels with or without levels of luteinising hormone (LH) and
follicle-stimulating hormone (FSH)] and the timing and frequency
of confirmation tests are not well established and there was sub-
stantial discussion among panel members. It was decided, as a
compromise, to recommend serial measures of serum oestradiol
during the initial months of treatment with an AIþ LHRH agonist.
When a LHRH agonist is used, the majority of the panel recom-
mends the use of the q4w (every 4 weeks) regimen. There are,
however, some recent data regarding the use of the 3-monthly
regimen with concurrent tamoxifen that yielded similar results in
terms of pharmacodynamic and safety profiles [12, 13] in two
randomised trials of 222 and 170 patients, respectively, and may,
therefore, be considered a valid option when combined with
tamoxifen for selected patients.
Section II: General guidelines
Continued
Guideline statement LoE/GoR Consensus
the same organ), potentially amenable
for local treatment, aimed at achieving a
complete remission status.
Patients with multiple chronic condi-
tions are deﬁned as patients with add-
itional comorbidities (e.g. cardiovascular,
impaired renal or liver function, auto-
immune disease) making it difﬁcult to
account for all of the possible extrapola-
tions to develop speciﬁc recommenda-
tions for care.
Expert opinion/
n/a
100%
Adequate OFS in the context of ABC:
Adequate OFS for ABC pre-menopausal
patients can be obtained through bilat-
eral ovariectomy, continuous use of
LHRH agonists or OFA through pelvic RT
(this latter is not always effective and
therefore is the least preferred option).
I/A 85%
If a LHRH agonist is used in this age group,
it should usually be given on a q4w
basis to guarantee optimal OFS.
II/B 85%
Efﬁcacy of OFS must be initially conﬁrmed
analytically through serial evaluations of
serum oestradiol, even in the presence
of amenorrhoea, especially if an AI is
administered.
Expert opinion/
B
85%
As all endocrine interventions for pre-
menopausal patients with endocrine-re-
sponsive ABC require indeﬁnite OFS,
choosing one method over the other
requires balance of patient’s wish for po-
tentially preserving fertility, compliance
with frequent injections over a long
period of time and cost.
Expert opinion/
B
85%
Maintenance therapy: in the context of
ABC Guidelines, maintenance therapy
refers to the continuation of anti-HER2
therapy and/or ET after discontinuation
of ChT.
Expert opinion/
n/a
100%
Integrative medicine: complementary
and integrative medicine (CIM) repre-
sents the use of complementary treat-
ments side by side with conventional
approaches in a proper therapeutic
environment.
Expert opinion/
n/a
100%
In green, NEW ABC 4 statements.
ABC, advanced breast cancer; AI, aromatase inhibitor; Consensus, per-
centage of panel members in agreement with the statement; ChT,
chemotherapy; ET, endocrine therapy; GoR, grade of recommendation;
HER2, human epidermal growth factor 2; LHRH, luteinising hormone-
releasing hormone; LoE, available level of evidence; OFA, ovarian function
ablation; OFS, ovarian function suppression; PD, disease progression;
q4w, every 4weeks; RT, radiotherapy.
Guideline statement LoE/GoR Consensus
The management of ABC is complex and,
therefore, involvement of all appropriate
specialties in a multidisciplinary team
(including but not restricted to medical,
radiation, surgical oncologists, imaging
experts, pathologists, gynaecologists,
psycho-oncologists, social workers,
nurses and palliative care specialists), is
crucial.
Expert opinion/
A
100%
From the time of diagnosis of ABC,
patients should be offered appropriate
psychosocial care, supportive care and
symptom-related interventions as a rou-
tine part of their care. The approach
must be personalised to meet the needs
of the individual patient.
Expert opinion/
A
100%
Continued
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Continued
Guideline statement LoE/GoR Consensus
Following a thorough assessment and con-
ﬁrmation of ABC, the potential treatment
goals of care should be discussed. Patients
should be told that ABC is incurable but
treatable, and that some patients can live
with ABC for extended periods of time
(many years in some circumstances).
Expert opinion/
A
97%
This conversation should be conducted in
the accessible language, respecting pa-
tient privacy and cultural differences,
and whenever possible, written informa-
tion should be provided.
Expert opinion/
A
97%
All ABC patients should be offered compre-
hensive, culturally sensitive, up-to-date and
easy-to-understand information about
their disease and its management.
I/A 97%
Patients (and their families, caregivers or
support network, if the patient agrees)
should be invited to participate in the
decision-making process at all times.
When possible, patients should be
encouraged to be accompanied by per-
sons who can support them and share
treatment decisions (e.g. family mem-
bers, caregivers, support network).
Expert opinion/
A
100%
Every ABC patient must have access to op-
timal cancer treatment and supportive
care according to the highest standards
of patient-centred care, as deﬁned by:
• Open communication between
patients and their cancer care teams
as a primary goal.
• Educating patients about treatment
options and supportive care, through
development and dissemination of
evidence-based information in a clear,
culturally appropriate form.
• Encouraging patients to be proactive in
their care and to share decision making
with their healthcare providers.
• Empowering patients to develop the
capability of improving their own QoL
within their cancer experience.
• Always taking into account patient
preferences, values and needs as es-
sential to optimal cancer care.
Expert opinion/
A
100%
Every ABC patient should:
 Have access to the most up-to-date
treatments and to innovative therapies
at accessible Breast Units/Centres.
Expert opinion/
A
100%
 Be treated in Specialist Breast Units/
Centres/Services (SBUs) by a special-
ised multidisciplinary team including
specialised side effects management
and a nurse experienced in the treat-
ment of ABC.
I/A
Continued
Continued
Guideline statement LoE/GoR Consensus
 Survivorship issues and palliative care
should be addressed and offered at
an early stage.
Expert opinion/
A
 A quality assurance programme cov-
ering the entire breast cancer path-
way from screening and diagnosis to
treatment, rehabilitation, follow-up
and palliative care including services
and support for ABC patients and
their caregivers, should be imple-
mented by SBUs.
Expert opinion/
B
General: QoL
Strong consideration should be given to
the use of validated PROMs for patients
to record the symptoms of disease and
side effects of treatment experienced as
a regular part of clinical care. These
PROMs should be simple and user-
friendly to facilitate their use in clinical
practice, and thought needs to be given
to the easiest collection platform, e.g.
tablets or smartphones. Systematic
monitoring would facilitate communica-
tion between patients and their treat-
ment teams by better characterising the
toxicities of all anticancer therapies. This
would permit early intervention of sup-
portive care services enhancing QoL.
I/C 87%
Speciﬁc tools for evaluation of QoL in ABC
patients should be developed.
Expert opinion/
A
100%
Until then, trials evaluating QoL in this set-
ting should use standardised PROs (in-
stead of focusing exclusively on CTCAEs)
and incorporate speciﬁc site and treat-
ment speciﬁc modules or subscales that
exist both in the EORTC and FACT
systems.
Expert opinion/
A
100%
Additionally, attention needs to be paid to
collection methods, timing of assess-
ments and handling of missing data.
More sophisticated statistics should also
be employed to ensure that clinicians
have better, reliable data to help
patients when choosing between treat-
ment options.
Expert opinion/
A
100%
General: clinical trials
There are few proven standards of care in
ABC management. After appropriate
informed consent, inclusion of patients
in well-designed, prospective, independ-
ent trials must be a priority whenever
such trials are available, and the patient
is willing to participate.
Expert opinion/
A
100%
The ABC community strongly calls for clin-
ical trials addressing important un-
answered clinical questions in this
Expert opinion/
A
100%
Continued
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The majority of general recommendations from previous ABC
conferences still stand as all available new data reinforces the
guidelines and, in some cases, increases the LoE and/or GoR.
Access to the best available therapies as well as treatment by a
specialised and multidisciplinary team are crucial to achieve the
best outcomes. However, access to treatments is very
Continued
Guideline statement LoE/GoR Consensus
setting, and not just for regulatory pur-
poses. Clinical trials should continue to
be carried out, even after approval of a
new treatment, providing real world
data on its performance, efﬁcacy and
toxicity.
General: affordability/cost-
effectiveness
The medical community is aware of the
problems raised by the cost of ABC
treatment. Balanced decisions should be
made in all instances; patients’ well-
being, length of life and preferences
should always guide decisions.
Expert opinion/
A
100%
We strongly recommend the use of object-
ive scales, such as the ESMO-MCBS or
the ASCO Value Framework, to evaluate
the real magnitude of beneﬁt provided
by a new treatment and help prioritise
funding, particularly in countries with
limited resources.
Expert opinion/
A
88%
The ABC community strongly supports the
use of BIOSIMILARS both for treatment
of breast cancer (i.e. trastuzumab) and
for supportive care (i.e. growth factors).
To be used, the biosimilar must be
approved after passing the stringent de-
velopment and validation processes
required by the EMA or the FDA or other
similarly strict authority.
I/A 90%
General: survivorship
As survival is improving in many patients
with ABC, consideration of survivorship
issues should be part of the routine care
of these patients. Health professionals
should therefore be ready to change
and adapt treatment strategies to dis-
ease status, treatment adverse effects
and QoL, patients’ priorities and life
plans. Attention to chronic needs for
home and family care, job and social
requirements should be incorporated in
the treatment planning and periodically
updated.
Expert opinion/
A
95%
ABC patients who desire to work or need
to work for ﬁnancial reasons should
have the opportunity to do so, with
needed and reasonable ﬂexibility in their
working schedules to accommodate
continuous treatment and hospital
visits.
Expert opinion/
A
100%
ABC patients with stable disease, being
treated as a ‘chronic condition’, should
Expert opinion/
B
82%
Continued
Continued
Guideline statement LoE/GoR Consensus
have the option to undergo breast re-
construction if clinically appropriate.
In ABC patients with long-standing stable
disease, screening breast imaging
should be an option.
Expert opinion/
C
Yes: 53%
No: 47%
Breast imaging should also be carried out
when there is a suspicion of locore-
gional progression.
I/A 100%
Fertility preservation: the impact of the
anticancer therapies on fertility should
be discussed with all women with ABC
of childbearing age and their partners,
before the start of treatment. The discus-
sion must also include appropriate infor-
mation about the prognosis of the
disease and the potential consequences
of pregnancy (e.g. stopping ongoing
treatment).
Expert opinion/
B
100%
General: other
Specialised oncology nurses (if possible
specialised breast nurses) should be part
of the multidisciplinary team managing
ABC patients. In some countries, this role
may be played by a physician assistant
or another trained and specialised
healthcare practitioner.
Expert opinion/
A
92%
The use of TELEMEDICINE in oncology to
help management of patients with ABC
living in remote places is an important
option to consider when geographic
distances are a problem and provided
that issues of connectivity are solved.
Expert opinion/
B
93%
In green, NEW ABC 4 statements.
ABC, advanced breast cancer; ASCO, American Society of Clinical
Oncology; Consensus, percentage of panel members in agreement with
the statement; CTCAE, Common Terminology Criteria for Adverse Events;
EMA, European Medicines Agency; EORTC, European Organisation for
Research and Treatment of Cancer; ESMO-MCBS, European Society for
Medical Oncology Magnitude of Clinical Beneﬁt Scale; FACT, Functional
Assessment of Cancer Therapy; FDA, Food and Drug Administration; GoR,
grade of recommendation; LoE, available level of evidence; PRO, patient-
reported outcome; PROM, patient-reported outcome measure; QoL, qual-
ity of life.
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heterogeneous between different countries and within each coun-
try, depending largely on financial, reimbursement and coverage
issues. All guidelines that are related to a certain treatment de-
pend, obviously, on the availability of that treatment. In all ABC
guidelines, when ‘preferred option’ or ‘standard of care’ terms
are used, they assume availability of the agent(s) discussed.
Currently, some efforts are being made to adapt the ABC
Guidelines to different environments, such as Africa, South
America and Asia, but these are separate projects, outside the
scope of the main guidelines and this manuscript.
One possible way to minimise the issue of cost is the use of bio-
similars. In line with the ESMO position [14], the ABC commu-
nity strongly supports the use of biosimilars both for treatment of
breast cancer (i.e. trastuzumab) and for supportive care (i.e.
growth factors). Importantly, only those biosimilars that pass the
stringent development and validation processes required by the
EMA or the Food and Drug Administration (FDA) or other simi-
larly strict authority should be used. Additionally, in order to
lead to a significant economic impact and making treatment
available to more patients with breast cancer, the price of biosimi-
lars should be substantially lower than the original compounds.
Accessibility to multidisciplinary care is also very uneven
throughout the world, for all cancer patients but particularly for
advanced cancer patients, who usually continue to be managed by
a single isolated physician. In Europe, the fight for the establish-
ment of Specialised Breast Units/Centres/Services (SBUs) has been
long and slow, with scattered implementation despite recommen-
dations from the European Parliament for the last decade [15].
Fortunately, some ABC patients can now live several years, espe-
cially those who achieve long-lasting complete remissions. This is
more frequent in situations of oligometastatic disease or with
HER2-positive disease. Survivorship issues have therefore started
to be discussed also for ABC patients. A highly sensitive issue is fer-
tility preservation and motherhood in ABC patients. Every patient
has the right to be informed about the potential negative impact
on fertility of anticancer therapies. This is particularly complex for
luminal ABC where induction of OFS or OFA is the mainstay of
therapy. If a desire for pregnancy exists or if pregnancy inadvert-
ently occurs, a delicate and thorough discussion should occur with
the patient and partner regarding the long-term prognosis of the
disease and the potential consequences of stopping any ongoing
therapy. However, after full information, the final decision lays
with the patient and should be respected [16–19].
Discussions about the risk/benefits of different further active
anticancer treatments in ABC can be challenging, especially if the
drugs offered might not reduce symptom burden or prolong sur-
vival but do have significant toxicities. Patients need good infor-
mation, collected systematically with reliable tools, about likely
harms and benefits to enable balanced decision making.
Although more trials of novel therapies do now build in health-
related QoL (HRQoL) assessment, many publications still give
precedence to physician recorded side effects grades using
Common Terminology Criteria for Adverse Events (CTCAE) cri-
teria rather than patient-reported outcomes (PROs). Studies
show that for many common toxicities, there is poor concord-
ance between physician reported and patient-reported side effects
in terms of both frequency and severity. Even when trials do em-
ploy standardised PROs, they are often inappropriate measures,
more suitable for use in early-stage disease. Both the European
Organisation for Research and Treatment of Cancer (EORTC)
and Functional Assessment of Cancer Therapy (FACT) systems
have site and treatment specific modules or subscales that should
be incorporated with more generic HRQoL measures.
Additionally, attention needs to be paid to collection methods,
timing of assessments and handling of missing data. More sophis-
ticated statistics should also be employed to ensure that clinicians
have better, reliable data to help patients when choosing between
treatment options. In addition, specific tools developed for
HRQoL assessment in ABC patients are needed and are the goal
of an ongoing collaborative project between the EORTC Quality
of Life and Breast Cancer Groups.
Section III: Assessment and treatment
general guidelines
Guideline statement LoE/GoR Consensus
Image and disease assessment
guidelines
Minimal staging work-up for ABC includes
a history and physical examination,
haematology and biochemistry tests,
and imaging of chest, abdomen and
bone.
II/A 67%
Brain imaging should not be routinely car-
ried out in asymptomatic patients. This
approach is applicable to all patients
with ABC including those with HER2-
positive and/or metastatic TNBC.
II/D 94%
The clinical value of tumour markers is not
well established for diagnosis or follow-
up after adjuvant therapy, but their use
(if elevated) as an aid to evaluate re-
sponse to treatment, particularly in
patients with non-measurable metastat-
ic disease, is reasonable. A change in
tumour markers alone should not be
used to initiate a change in treatment.
II/C 89%
Evaluation of response to therapy should
generally occur every 2–4 months for ET
or after two to four cycles for ChT,
depending on the dynamics of the
disease, the location and extent of meta-
static involvement and type of treat-
ment. Imaging of target lesions may be
sufﬁcient in many patients. In certain
patients, such as those with
indolent disease, less frequent monitor-
ing is acceptable. Additional testing
should be carried out in a timely
manner, irrespective of the planned
intervals, if PD is suspected or new
symptoms appear. Thorough history
and physical examination must always
be carried out.
Expert opinion/
B
81%
Continued
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Continued
Guideline statement LoE/GoR Consensus
Biopsy guidelines
A biopsy (preferably providing histology)
of a metastatic lesion should be carried
out, if easily accessible, to conﬁrm diag-
nosis particularly when metastasis is
diagnosed for the ﬁrst time.
I/B 98%
Biological markers (especially HR and
HER2) should be reassessed at least
once in the metastatic setting, if clinical-
ly feasible. Depending on the metastatic
site (e.g. bone tissue), technical consid-
erations need to be discussed with the
pathologist.
I/B 98%
If the results of tumour biology in the
metastatic lesion differ from the primary
tumour, it is currently unknown which
result should be used for treatment de-
cision making. Since a clinical trial
addressing this issue is difﬁcult to under-
take, we recommend considering the
use of targeted therapy (ET and/or anti-
HER2 therapy) when receptors are posi-
tive in at least one biopsy, regardless of
timing.
Expert opinion/
B
87%
Locoregional treatment general
guidelines
To date, the removal of the primary tu-
mour in patients with de novo stage
IV breast cancer has not been associ-
ated with prolongation of survival, with
the possible exception of the subset of
patients with bone-only disease.
However, it can be considered in
selected patients, particularly to improve
QoL, always taking into account the
patient’s preferences.
I/C 70%
Of note, some studies suggest that surgery
is only valuable if carried out with the
same attention to detail (e.g. complete
removal of the disease) as in patients
with early-stage disease. Additional pro-
spective clinical trials evaluating the
value of this approach, the best candi-
dates and best timing are currently
ongoing.
II/B 70%
A small but very important subset of
patients with ABC, for example those
with oligometastatic disease or low-
volume metastatic disease that is
highly sensitive to systemic therapy, can
achieve complete remission and a long
survival. A multimodal approach, includ-
ing locoregional treatments with cura-
tive intent, should be considered for
these selected patients. A prospective
clinical trial addressing this speciﬁc situ-
ation is needed.
Expert opinion/
B
91%
Continued
Continued
Guideline statement LoE/GoR Consensus
Systemic treatment general guidelines
Treatment choice should take into account
at least these factors: HR and HER2 sta-
tus, previous therapies and their toxic-
ities, DFI, tumour burden (deﬁned as
number and site of metastases), bio-
logical age, PS, comorbidities (including
organ dysfunctions), menopausal status
(for ET), need for a rapid disease/symp-
tom control, socio-economic and psy-
chological factors, available therapies in
the patient’s country and patient’s
preferences.
Expert opinion/
A
100%
The age of the patient should not be the
sole reason to withhold effective ther-
apy (in elderly patients) nor to overtreat
(in young patients). Age alone should
not determine the intensity of
treatment.
I/E 100%
ChT general guidelines
Both combination and sequential single-
agent ChT are reasonable options. Based
on the available data, we recommend
sequential monotherapy as the pre-
ferred choice for ABC. Combination ChT
should be reserved for patients with
rapid clinical progression, life-threaten-
ing visceral metastases or need for rapid
symptom and/or disease control.
I/A 96%
In the absence of medical contraindica-
tions or patient concerns, anthracycline-
or taxane-based regimens, preferably as
single agents, would usually be consid-
ered as ﬁrst-line ChT for HER2-negative
ABC, in those patients who have not
received these regimens as (neo)adju-
vant treatment and for whom ChT is ap-
propriate. Other options are, however,
available and effective, such as capecita-
bine and vinorelbine, particularly if
avoiding alopecia is a priority for the
patient.
I/A 71%
In patients with taxane-naive and anthracy-
cline-resistant ABC or with anthracycline
maximum cumulative dose or toxicity
(i.e. cardiac) who are being considered
for further ChT, taxane-based therapy,
preferably as single agent, would usually
be considered as treatment of choice.
Other options are, however, available
and effective, such as capecitabine and
vinorelbine, particularly if avoiding alo-
pecia is a priority for the patient.
I/A 59%
In patients pre-treated (in the adjuvant
and/or metastatic setting) with an
anthracycline and a taxane, and who do
not need combination ChT, single-agent
I/A 77%
Continued
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Section IV: ER-positive/HER2-negative
(luminal) ABC
Continued
Guideline statement LoE/GoR Consensus
capecitabine, vinorelbine or eribulin are
the preferred choices. Additional
choices include gemcitabine, platinum
agents, taxanes and liposomal anthracy-
clines. The decision should be individu-
alised and take into account different
toxicity proﬁles, previous exposure, pa-
tient preferences and country
availability.
If given in the adjuvant setting, a taxane can
be re-used as ﬁrst-line therapy, particular-
ly if there has been at least 1 year of DFS.
I/B 92%
If given in the adjuvant setting, provided
that maximum cumulative dose has not
been achieved and that there are no
cardiac contraindications, anthracyclines
can be re-used in ABC, particularly if
there has been at least 1 year of DFS.
I/B 93%
Metronomic ChT is a reasonable treat-
ment option for patients not requiring
rapid tumour response. The better
studied regimen is CM (low-dose oral
cyclophosphamide and methotrexate);
other regimens are being evaluated
(including capecitabine and vinorelbine).
Randomised trials are needed to accur-
ately compare metronomic ChT with
standard dosing regimens.
I/B 88%
Duration of each regimen and the number
of regimens should be tailored to each
individual patient.
Expert opinion/
A
96%
Usually each regimen (except anthracy-
clines) should be given until PD or un-
acceptable toxicity. What is considered
unacceptable should be deﬁned to-
gether with the patient.
I/B 72%
Other agents
Bevacizumab combined with ChT as ﬁrst-
or second-line therapy for ABC provides
only a moderate beneﬁt in PFS and no
beneﬁt in OS. The absence of known pre-
dictive factors for bevacizumab efﬁcacy
renders recommendations on its use difﬁ-
cult. Bevacizumab can only therefore be
considered as an option in selected cases
in these settings and is not recom-
mended after ﬁrst/second line.
I/C 74%
No new statements for this section were developed at ABC 4.
ABC, advanced breast cancer; ChT, chemotherapy; Consensus, percent-
age of panel members in agreement with the statement; ET, endocrine
therapy; DFI, disease-free interval; DFS, disease-free survival; GoR, grade
of recommendation; HER2, human epidermal growth factor 2; HR, hor-
mone receptor; LoE, available level of evidence; OS, overall survival; PD,
disease progression; PFS, progression-free survival; PS, performance sta-
tus; QoL, quality of life; TNBC, triple-negative breast cancer.
Guideline statement LoE/GoR Consensus
ET is the preferred option for HR-positive
disease, even in the presence of visceral
disease, unless there is visceral crisis or
concern/proof of endocrine resistance.
I/A 93%
Many trials in ER-positive ABC have not
included PRE-MENOPAUSAL women.
Despite this, we recommend that young
women with ER-positive ABC should
have adequate OFS/OFA and then be
treated in the same way as post-meno-
pausal women, with endocrine agents
and with or without targeted therapies.
Expert opinion/
A
95%
Future trials exploring new endocrine-
based strategies should be designed to
allow for enrolment of both pre- and
post-menopausal women, and men.
Expert opinion/
A
92%
For pre-menopausal women, for whom ET
was decided, OFS/OFA combined with
additional ET is the preferred choice.
I/A 93%
OFA by laparoscopic bilateral oophorec-
tomy ensures deﬁnitive oestrogen sup-
pression and contraception, avoids
potential initial tumour ﬂare with LHRH
agonist and may increase eligibility for
clinical trials. Patients should be
informed on the options of OFS/OFA
and decisions should be made on a
case-by-case basis.
Expert opinion/
C
91%
Single-agent tamoxifen is the only avail-
able endocrine option for pre-meno-
pausal women who decline OFS/OFA,
but the panel believes it is a less effect-
ive option.
I/D 92%
The preferred ﬁrst-line ET depends on the
type and duration of adjuvant ET as well
as the time elapsed from the end of ad-
juvant ET; it can be an AI, tamoxifen or
fulvestrant, for pre- and peri-meno-
pausal women with OFS/OFA, men
(preferably with LHRH agonist) and
post-menopausal women.
I/A 84%
The addition of a CDK 4/6 inhibitor to an
AI, in patients naı¨ve or pre-exposed to
ET, provided a signiﬁcant improvement
in median PFS (10 months), with an
acceptable toxicity proﬁle, and is, there-
fore, one of the preferred treatment
options for pre- and peri-menopausal
women with OFS/OFA, men (preferably
with LHRH agonist) and post-meno-
pausal women. Patients relapsing <12
months from the end of adjuvant AI
I/A 90%
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Most of the revised guidelines at ABC 4 relate to ER-positive/
HER2-negative or luminal ABC, in which most of the recent
advances in the field occurred. As in previous ABC guidelines and
in accordance with all national guidelines, the preferred treat-
ment for luminal ABC is endocrine therapy (ET) in the majority
of cases, excluding only those with visceral crisis or concern or
Continued
Guideline statement LoE/GoR Consensus
were not included in the published
studies and may not be suitable for this
combination. OS results are still awaited.
QoL was comparable to that with ET
alone.
ESMO-MCBS v1.1 score: 3
The addition of a CDK 4/6 inhibitor to ful-
vestrant, in patients previously exposed
to ET, provided signiﬁcant improvement
in median PFS (6–7 months) as well
as improvement in QoL, and is one of
the preferred treatment options, if a
CDK 4/6 inhibitor was not previously
used, for pre- and peri-menopausal
women with OFS/OFA and post-
menopausal women and men.
OS results are awaited.
I/A 90%
ESMO-MCBS v1.1 score: 4
The addition of everolimus to an AI is a
valid option for some patients [for pre-
and peri-menopausal women with OFS/
OFA, men (preferably with LHRH agon-
ist) and post-menopausal women] previ-
ously exposed to ET, since it signiﬁcantly
prolongs PFS, albeit without evidence of
OS beneﬁt. The decision to treat must
take into account the toxicities associ-
ated with this combination, lack of stat-
istical signiﬁcant OS beneﬁt, cost and
availability.
I/B 88%
ESMO-MCBS v1.1 score: 2
Tamoxifen or fulvestrant can also be com-
bined with everolimus.
II/B 80%
Adequate prevention, close monitoring
and proactive treatment of adverse
events is needed, particularly in older
patients treated with everolimus due to
the increased incidence of toxic deaths
reported in the BOLERO-2 trial.
I/B 97%
The optimal sequence of endocrine-based
therapy is uncertain. It depends on
which agents were previously used [in
the (neo)adjuvant or advanced settings],
the burden of the disease, patients’ pref-
erence, costs and availability. Available
options [for pre- and peri-menopausal
women with OFS/OFA, men (preferably
with LHRH agonist) and post-meno-
pausal women] include AI, tamoxifen,
fulvestrant, AI/fulvestrant þ CDK 4/6 in-
hibitor, AI/tamoxifen/fulvestrant þ ever-
olimus. In later lines, also megestrol
acetate and oestradiol, as well as repeti-
tion of previously used agents, may be
used.
I/A 95%
Continued
Continued
Guideline statement LoE/GoR Consensus
It is currently unknown how the different
combinations of endocrine þ targeted
agents compare with each other, and
with single-agent ChT. Trials are
ongoing.
Everolimus and CDK 4/6 inhibitors should
not be used after PD on that speciﬁc
agent (i.e. beyond progression).
n/a/E 74%
At present, no validated predictive
biomarkers other than HR status exist to
identify patients who will/will not
beneﬁt from the addition of a targeted
agent (i.e. CDK 4/6 inhibitor, mTOR
inhibitor) to ET and none of the
studied biomarkers is ready for use in
clinical practice. Research efforts must
continue.
I/E 95%
The combination of a non-steroidal AI and
fulvestrant as ﬁrst-line therapy for post-
menopausal patients resulted in signiﬁ-
cant improvement in both PFS and OS
compared with AI alone in one phase III
trial and no beneﬁt in a second trial with
a similar design. Subset analysis sug-
gested that the beneﬁt was limited to
patients without prior exposure to adju-
vant ET (tamoxifen). Based on these
data, combination ET may be offered to
some patients with ABC without prior
exposure to adjuvant ET.
II/C Yes: 33%
No: 53%
Abstain: 14%
Concomitant ChT and ET has not shown a
survival beneﬁt and should not be car-
ried out outside a clinical trial.
II/D 100%
Endocrine treatment after ChT (mainten-
ance ET) to maintain beneﬁt is a reason-
able option, though it has not been
assessed in randomised trials.
III/B 88%
In green, NEW ABC 4 statements.
ABC, advanced breast cancer; AI, aromatase inhibitor; CDK, cyclin-
dependent kinase; ChT, chemotherapy; Consensus, percentage of panel
members in agreement with the statement; ER, oestrogen receptor;
ESMO-MBCS, European Society for Medical Oncology Magnitude of
Clinical Beneﬁt Scale; ET, endocrine therapy; GoR, grade of recommenda-
tion; HER2, human epidermal growth factor 2; HR, hormone receptor;
LHRH, luteinising hormone-releasing hormone; LoE, available level of evi-
dence; mTOR, mechanistic target of rapamycin; OFA, ovarian function ab-
lation; OFS, ovarian function suppression; OS, overall survival; PD, disease
progression; PFS, progression-free survival; QoL, quality of life.
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proof for endocrine resistance (both defined in Section I).
Unfortunately, this recommendation continues to be very often
ignored in current clinical practice, mainly due to financial rea-
sons and reimbursement rules that are not patient-focused, that
pressure for the use of i.v. therapies (discussed in [20]).
Two conceptual changes were introduced at ABC 4 regarding
pre-menopausal patients and lines of therapy. As previously dis-
cussed, the optimal management of pre-menopausal patients
with luminal ABC consists of the induction of OFS or OFA, in
combination with another endocrine agent [21]. Since the first
step is to render the patient post-menopausal, we believe that all
other recommendations should be common to both post-meno-
pausal and initially pre- or peri-menopausal patients.
Furthermore, resources should not be wasted running duplicate
and separate trials for pre- and post-menopausal patients, but ra-
ther pre-menopausal patients should be eligible for trials if OFS
or OFA is carried out. The definition of optimal OFS/OFA in the
context of ABC is described in Section I. Furthermore, the ABC
panel strongly advocates against unrealistic, unnecessary and
sometimes expensive clinical trial requirements on contracep-
tion, with clear negative impact on QoL, for pre-menopausal
women who do not undergo OFS/OFA, such as multiple contra-
ceptive methods [e.g. intrauterine device (IUD) plus condoms
plus spermicide] or complete abstinence, which are sometimes
required to be continued for 6 months after the completion of
study drug.
The choice among different available agents as well as their se-
quence depends largely on which agents were previously adminis-
tered and the response obtained, due to the link with endocrine
resistance. For this reason, previous exposure, and not only line
of treatment, should guide the recommendations.
With the publication of the Falcon study [22], available
options for initial single-agent ET include an AI, fulvestrant and
tamoxifen. The choice will be largely determined by previous ex-
posure in the adjuvant setting.
The last 2 years saw the approval of three cyclin-dependent kin-
ase (CDK) inhibitors—palbociclib, ribociclib and abemaciclib—
by the FDA and the first two by the EMA (it is foreseen that
abemaciclib will soon be approved by EMA as well). Currently,
several open questions remain regarding the optimal integration
of these agents in clinical practice, such as: (i) accurate identifica-
tion, if possible by biomarkers, of the patients who need the com-
bination of ET and a CDK inhibitor, those who need to be treated
with chemotherapy (ChT) and those who can be adequately
treated with endocrine agents alone; (ii) optimal sequence for the
individual patient and (iii) optimal treatment after progression
on CDK inhibitors.
When applying the ESMO-MCBS version 1.1 [9] to each drug
in each setting, both efficacy and toxicity/QoL must be taken into
account. Unfortunately, and as discussed above, some trials do
not assess HRQoL and others do not use the most adequate tools
to assess it. The use of CDK inhibitors in the first-line setting has
been associated with a substantial (about 10 months) benefit in
PFS [23–29], while OS results are still awaited. They have a fa-
vourable safety profile, with neutropaenia not associated with
infections being the most common side effect. However, in this
setting their use has not been associated with an improvement in
HRQoL [30, 31], except perhaps in MONALEESA-7 [27]. A
more recent evaluation in PALOMA-2 indicates that disease
progression (PD) is associated with degradation of HRQoL,
both in the palbociclib arm and the placebo arm [32]. For the
reasons described, the use of a CDK inhibitor in the first-line
setting reaches an ESMO-MCBS score of 3. In the second-line
setting, their use has been associated with a 6–7 months
progression-free survival (PFS) benefit [33, 34] and an HRQoL
improvement [35, 36], and hence their ESMO-MCBS score is
4. There are some differences in the safety profile among the
three CDK inhibitors, with less neutropaenia and more diar-
rhoea associated with abemaciclib, less hepatotoxicity with pal-
bociclib and potential for QT interval prolongation with
ribociclib. Abemaciclib has shown important single-agent ac-
tivity [37, 38] as well as potential for crossing the blood-brain
barrier [39].
Combination of an endocrine agent (AI, tamoxifen or fulves-
trant) with everolimus has shown a PFS benefit, albeit without a
statistically significant OS benefit [40, 41] in the second-line set-
ting and, more recently, also in the first-line setting [42], and is
an available option for patients previously exposed to ET. Its use
is associated with substantial toxicity, which downgrades its
ESMO-MCBS score to 2. However, as more experience is gained
regarding the use of everolimus and the management of its toxic-
ities, its clinical use becomes easier, in particular regarding man-
agement of mucositis, as described in Section XII. Adequate
prevention, close monitoring and proactive treatment of adverse
events is needed, particularly in older patients treated with evero-
limus due to the increased incidence of toxic deaths reported in
the BOLERO-2 trial [43].
Areas where research efforts must continue are predictive bio-
markers, optimal sequence and best management for patients
who progressed during or less than 1 year after adjuvant AIs, since
these patients have been consistently and unfortunately excluded
from most first-line therapy trials.
Section V: HER2-positive ABC
Guideline statement LoE/GoR Consensus
Anti-HER2 therapy should be offered early
(as ﬁrst line) to all patients with HER2-
positive ABC, except in the presence of
contraindications to the use of such
therapy.
I/A 98%
Patients progressing on an anti-HER2 ther-
apy combined with a cytotoxic or endo-
crine agent should be offered additional
anti-HER2 therapy with subsequent
treatment, except in the presence of
contraindications, since it is beneﬁcial to
continue suppression of the HER2 path-
way. The choice of the anti-HER2 agent
will depend on country-speciﬁc avail-
ability, the speciﬁc anti-HER2 therapy
previously administered and the re-
lapse-free interval. The optimal
I/A 91%
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Continued
Guideline statement LoE/GoR Consensus
sequence of all available anti-HER2
therapies is currently unknown.
The optimal duration of anti-HER2 ther-
apy for ABC (i.e. when to stop these
agents) is currently unknown.
In patients achieving a complete remission,
the optimal duration of maintenance
anti-HER2 therapy is unknown and
needs to be balanced against treatment
toxicity, logistical burden and cost.
Stopping anti-HER2 therapy after several
years of sustained complete remission
may be considered in some patients,
particularly if treatment rechallenge is
available in case of progression.
Expert opinion/
C
93%
Patients who have received any type of
(neo)adjuvant anti-HER2 therapy should
not be excluded from clinical trials for
HER2-positive ABC. These patients re-
main candidates for anti-HER2 therapies.
I/B 100%
For the highly selected patientsa with ER-
positive/HER2-positive ABC, for whom
ET þ anti-HER2 therapy was chosen as
ﬁrst-line therapy, dual anti-HER2 block-
ade (with either pertuzumab þ trastuzu-
mab or lapatinib þ trastuzumab) can be
used since it provides a beneﬁt in PFS.
This decision must be balanced against
the higher side effects, higher costs and
lack of OS beneﬁt so far, when com-
pared with ET þ anti-HER2
monotherapy.
I/B 80%
For patients with ER-positive/HER2-positive
ABC, for whom ChT þ anti-HER2 therapy
was chosen as ﬁrst-line therapy and pro-
vided a beneﬁt, it is reasonable to use ET
þ anti-HER2 therapy as maintenance
therapy, after stopping ChT, although
this strategy has not been studied in
randomised trials. Duration of mainten-
ance therapy should be until progres-
sion, unacceptable toxicity or patient
request and needs to be evaluated in
clinical trials. There are no data to decide
between single-agent anti-HER2 or dual
blockade, to combine with maintenance
ET after stopping ChT, in ER-positive/
HER2-positive ABC.
n/a/B 80%
In the ﬁrst-line setting, for HER2-positive
ABC previously treated (in the adjuvant
setting with DFI >12 months) or un-
treated with trastuzumab, combinations
of ChT þ trastuzumab are superior to
combinations of ChT þ lapatinib in
terms of PFS and OS.
I/A 95%
Continued
Continued
Guideline statement LoE/GoR Consensus
The standard ﬁrst-line therapy for patients
previously untreated with anti-HER2
therapy is the combination of ChT þ
trastuzumab and pertuzumab, because
it has proven to be superior to ChT þ
trastuzumab in terms of OS in this
population.
I/A 86%
For patients previously treated [in the
(neo)adjuvant setting] with anti-HER2
therapy, the combination of ChT þ
trastuzumab and pertuzumab is an
important option for ﬁrst-line therapy.
Few (88) of these patients were treated
in the CLEOPATRA trial and all with tras-
tuzumab-free interval >12 months.
I/A 76%
There are currently no data supporting the
use of dual blockade with trastuzumab
þ pertuzumab and ChT beyond pro-
gression (i.e. continuing dual blockade
beyond progression) and therefore this
three-drug regimen should not be given
beyond progression outside clinical
trials.
Expert opinion/
E
86%
In a HER2-positive ABC patient, previously
untreated with the combination of ChT
þ trastuzumab þ pertuzumab, it is ac-
ceptable to use this treatment after ﬁrst
line.
II/B 76%
After ﬁrst-line, trastuzumab-based therapy,
T-DM1 provides superior efﬁcacy relative
to other HER2-based therapies in the se-
cond line (versus lapatinib þ capecita-
bine) ‘and beyond’ (versus treatment of
physician’s choice). T-DM1 should be
preferred in patients who have pro-
gressed through at least one line of tras-
tuzumab-based therapy, because it
provides an OS beneﬁt. However, there
are no data on the use of T-DM1 after
dual blockade with trastuzumab þ
pertuzumab.
I/A 88%
In case of progression on trastuzumab-
based therapy, the combination trastu-
zumab þ lapatinib is a reasonable
treatment option for some patients.
There are however, no data on the use
of this combination after progression on
pertuzumab or T-DM1.
I/B 84%
Regarding the ChT component of
HER2 positive ABC treatment:
I/A 88%
When pertuzumab is not given, ﬁrst-line
regimens for HER2 ABC can include tras-
tuzumab combined with vinorelbine or
a taxane. Differences in toxicity between
these regimens should be considered
Continued
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In ABC 3, almost all guidelines for the management of HER2-
positive ABC were reviewed, and few new data were presented/
published in the last 2 years. The exception is related to the sub-
group of ER-positive/HER2-positive disease for which the
ALTERNATIVE trial results were presented at ASCO 2017 [44].
This trial evaluated the role of ET þ anti-HER2 therapy (trastu-
zumab alone, lapatinib alone or dual blockade with
trastuzumab þ lapatinib) in 355 patients with ABC progressing
during or following prior trastuzumab þ ChT in the neo(adju-
vant) and/or first-line metastatic setting. Initially, the study was
designed to evaluate the OS benefit of ETþ trastuzumabþ lapa-
tinib, and it had been a request from the regulatory agencies for
the development of lapatinib. With the publication of the
CLEOPATRA trial [45] results showing a substantial OS benefit,
a non-data-driven protocol amendment was made to change the
primary endpoint to PFS, in agreement with the regulatory
authorities. For the primary comparison, ALTERNATIVE has
shown a PFS benefit of 5.3 months for ETþ dual blockade versus
ET þ trastuzumab [11.0 versus 5.7 months; hazard ratio (HR):
0.62 (0.45, 0.88), P¼ 0.0064]. As a secondary endpoint, PFS was
compared between the three arms showing a PFS of 8.1 months
for ET þ lapatinib. OS was not statistically significantly different
in the three arms: 46 versus 40 versus 45 months for the dual
blockade, trastuzumab and lapatinib arms, respectively.
After considering all available data on both ET and ChT com-
binations with anti-HER2 agents, a small update was made to the
guideline but retaining its main message, i.e. in the absence of
valuable biomarkers, the approach of ET þ anti-HER2 agents
should be reserved for highly selected patients, including those
with contraindications to ChT, patients with a strong preference
against ChT or those with a long disease-free interval (DFI), min-
imal disease burden (in particular in terms of visceral involve-
ment) and/or strong ER/progesterone receptor (PgR) expression
[11]. Trials directly comparing ChT plus anti-HER2 therapy ver-
sus ET plus anti-HER2 therapy or assessing ET þ anti-HER2
therapy as maintenance are currently ongoing [Detect V/
CHEVENDO (NCT02344472), SYSUCC-002 (NCT01950182)
and PERNETTA trials], and their results will allow for better
recommendations.
Furthermore, in several countries, anti-HER2 therapy, namely
trastuzumab, can only be used once in the metastatic setting since
its use beyond progression is either not approved or not reim-
bursed; in those cases, preference should be given to a combin-
ation of ChT plus anti-HER2 therapy in view of the OS benefit
observed.
The use of a combination of ET plus anti-HER2 therapy as
maintenance therapy for ER-positive/HER2-positive ABC, after
initial cycles of ChT plus anti-HER2 therapy, is a reasonable op-
tion, most probably delaying PD and the consequent need for a
change in therapy. Duration of maintenance therapy should be
until progression, unacceptable toxicity or patient request and
needs to be evaluated in clinical trials since no randomised trials
exist. Of note, in the CLEOPATRA trial, maintenance therapy
was carried out with anti-HER2 agents alone, which is also an
option.
Continued
Guideline statement LoE/GoR Consensus
and discussed with the patient in mak-
ing a ﬁnal decision. Other ChT agents
can be administered with trastuzumab
but are not as well studied and are not
preferred.
For later lines of therapy, trastuzumab can
be administered with several ChT
agents, including but not limited to,
vinorelbine (if not given in ﬁrst line),
taxanes (if not given in ﬁrst line),
capecitabine, eribulin, liposomal
anthracyclines, platinum, gemcitabine
or metronomic CM. The decision should
be individualised and take into account
different toxicity proﬁles, previous
exposure, patient preferences and
country availability.
II/A 91%
ChT agents to combine with a dual block-
ade of trastuzumab þ pertuzumab are
docetaxel [I/A] or paclitaxel [I/B]. Also
possible are vinorelbine [II/A], nab-
paclitaxel [II/B] and capecitabine [II/A].
See in
statement
86%
aSee deﬁnition in text.
In green, NEW ABC 4 statements.
ABC, advanced breast cancer; ChT, chemotherapy; CM, low-dose oral
cyclophosphamide and methotrexate; Consensus, percentage of panel
members in agreement with the statement; DFI, disease-free interval; ER,
oestrogen receptor; ET, endocrine therapy; GoR, grade of recommenda-
tion; HER2, human epidermal growth factor 2; LoE, available level of evi-
dence; OS, overall survival; PFS, progression-free survival; T-DM1,
trastuzumab emtansine.
Guideline statement LoE/GoR Consensus
For non-BRCA-associated advanced TNBC,
there are no data supporting different or
speciﬁc ChT recommendations.
I/A 98%
Continued
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Section VI: Advanced TNBC
Few advances have also been made in these last 2 years in the
management of advanced triple-negative breast cancer (TNBC).
ChT remains the only available non-investigational systemic
treatment option for non-BRCA-mutated advanced TNBC, with
no specific recommendations regarding types of agents, with the
possible exception of platinum compounds.
The ongoing characterisation of different subgroups within
this breast cancer subtype, may lead to the development of spe-
cific therapies for each of the subgroups. One of these subgroups
is defined by an important expression of androgen receptor (AR;
luminal AR subtype). The fact that bicalutamide, an anti-
androgen approved for the treatment of prostate cancer, is avail-
able, has led to some off-label use in advanced TNBC. However,
the panel believes that this type of agent should not be used in
routine clinical practice, in view of the very limited data that
exist [46–48] and until the determination of the AR is optimised
and standardised. Unfortunately, the development of enzaluta-
mide, another anti-androgen, in breast cancer has been put on
hold.
Section VII: Hereditary ABCContinued
Guideline statement LoE/GoR Consensus
Therefore, all ChT recommendations for
HER2-negative disease also apply for
advanced TNBC.
In advanced TNBC patients (regardless of
BRCA status) previously treated with
anthracyclines with or without taxanes
in the (neo)adjuvant setting, carbopla-
tin demonstrated comparable efﬁcacy
and a more favourable toxicity proﬁle,
compared with docetaxel, and is,
therefore, an important treatment
option.
I/A 91%
The AR is a potential target in advanced
TNBC. There are, however, no standar-
dised methods to assay AR. Limited data
suggest a low level of efﬁcacy for AR an-
tagonist agents such as bicalutamide
and enzalutamide. At this time, these
agents should not be used in routine
clinical practice. More deﬁnitive trials are
needed, and research efforts must con-
tinue to optimise and standardise the
determination of AR.
II/D 85%
In green, NEW ABC 4 statements.
AR, androgen receptor; ChT, chemotherapy; Consensus, percentage of
panel members in agreement with the statement; GoR, grade of recom-
mendation; HER2, human epidermal growth factor 2; LoE, available level
of evidence; TNBC, triple-negative breast cancer.
Guideline statement LoE/GoR Consensus
Genetic testing
In the ABC setting, results from genetic test-
ing may have therapeutic implications
and should therefore be considered as
early as possible.
Expert opinion/
B
100%
Genes to be tested for depend on personal
and family history; however, at present, only
germline mutations in BRCA1/2 have proven
clinical utility and therapeutic impact.
I/A 100%
Testing for other additional moderate- to
high-penetrance genes may be considered,
if deemed appropriate by the geneticist/
genetic counsellor. However, it must be
clariﬁed to the patient that at present, a
mutation in another moderate- to high-
penetrance gene has no direct clinical
implications, for the patients themselves, in
the setting of ABC.
Expert opinion/
C
100%
The therapeutic implications of somatic
BRCA1/2 mutations in breast tumours need
to be further explored within a research set-
ting and should not be used for decision
making in routine clinical practice.
n/a/E 83%
BRCA-associated ABC
In patients with BRCA-associated advanced
TNBC or endocrine-resistant ABC previously
treated with an anthracycline with or with-
out a taxane (in the adjuvant and/or meta-
static setting), a platinum regimen is the
preferred option, if not previously adminis-
tered and no suitable clinical trial is available.
All other treatment recommendations are
similar to sporadic ABC.
II/A 86%
A PARPi (olaparib or talazaparib) is a rea-
sonable treatment option for patients with
BRCA-associated advanced TNBC or luminal
(after progression on ET) ABC, previously
treated with an anthracycline with/without a
taxane (in the adjuvant and/or metastatic
setting), since its use is associated with a PFS
beneﬁt, improvement in QoL and a favour-
able toxicity proﬁle. OS results are awaited. It
is unknown how PARPis compare with plat-
inum compounds in this setting and their
efﬁcacy in truly platinum-resistant tumours.
I/B 80%
In green, NEW ABC 4 statements.
ABC, advanced breast cancer; Consensus, percentage of panel members in
agreement with the statement; ET, endocrine therapy; GoR, grade of recom-
mendation; LoE, available level of evidence; OS, overall survival; PARPi, poly
adenosine diphosphate ribose polymerase inhibitor; PFS, progression-free
survival; QoL, quality of life; TNBC, triple-negative breast cancer.
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With the approval of olaparib, results from genetic testing in the
setting of ABC may have immediate therapeutic implications and
should therefore be carried out as early as possible. Genetic test-
ing should be guided by international/national guidelines [49]
and may also be considered for all patients with triple-negative
disease. Genes to be tested for depend on personal and family his-
tory, however at present only germline mutations in BRCA1/2
have any clinical utility and therapeutic impact.
Although BRCA1/2 are the most frequently mutated genes,
testing for other additional moderate- to high-penetrance genes
may be considered, if deemed appropriate by the geneticist/gen-
etic counsellor; however, it must be clarified to the patient that at
present a mutation in another moderate- to high-penetrance
gene has no direct clinical implications in the setting of ABC.
When a hereditary cancer syndrome is suspected in ABC and a
mutation in BRCA1/2 has not been identified, and the patient still
seeks information, multi-gene panel testing may be considered.
Practice should be guided by high-quality international/national
guidelines. As commercially available multi-gene panels include
different genes, the choices of the specific panel and quality-
controlled laboratory are crucial. Development of quality-
controlled genetic counselling services is strongly encouraged
[50, 51].
The OlympiAD trial [52] evaluated the role of the poly adeno-
sine diphosphate ribose polymerase (PARP) inhibitor olaparib
monotherapy in 302 patients with germline BRCA mutation and
advanced ER-positive/HER2-negative or TNBC, who had
received no more than two previous ChT regimens for metastatic
disease. If prior platinum was used, no evidence of progression
during treatment in the advanced setting or 12 months since
(neo)adjuvant platinum treatment was required. The comparator
was standard monoChT per physician’s choice (capecitabine, eri-
bulin or vinorelbine). Median PFS was longer in the olaparib
group [7.0 versus 4.2 months; HR: 0.58; 95% confidence interval
(CI): 0.43–0.80; P< 0.001]. At this follow-up time, there were no
differences in OS. Toxicity and rate of treatment discontinuation
due to side effects were higher in the ChT arm, while QoL was sig-
nificantly better in the olaparib arm.
In the San Antonio Breast Cancer Symposium 2017, the first
results of the EMBRACA trial were presented [53]. With a similar
design to OlympiAD, this trial evaluated the role of talazaparib in
431 ABC patients with a BRCA mutation, when compared with
monoChT per physician’s choice (capecitabine, eribulin, vinorel-
bine or gemcitabine). Most patients had not received prior
platinum-based therapy. At a median follow-up time of
11.2 months, PFS was longer in the talazaparib arm (8.6 versus
5.6 months; HR: 0.54; 95% CI: 0.41–0.71; P< 0.0001); no differ-
ence was seen, at this time, in OS and QoL was significantly better
in the talazaparib arm.
While these trials are positive and met their primary endpoint,
the benefit seen was less than anticipated. Nevertheless, the toler-
ability of these agents when given as monotherapy, the ChT-free
approach with improved QoL makes it an attractive option for
BRCA-related ABC. Further studies are needed to clarify the value
of PARP inhibitors in platinum-resistant disease, as well as their
value when compared with platinum compounds.
Section VIII: Precision medicine
Guideline statement LoE/GoR Consensus
Multigene panels, such as those
obtained using NGS or other tech-
nology on tumour DNA have not
yet proven beneﬁcial in clinical trials
for ABC, their impact on outcome
remains undeﬁned and should not
be used in routine clinical practice.
For patients who are suitable to par-
ticipate in clinical trials of novel
therapies and are readily able/moti-
vated to attend a centre with rele-
vant clinical trials, NGS testing may
be used in the context of prospect-
ive molecular triage programmes to
select patients for therapeutic trials.
Speciﬁc tests (as distinguished from
broad mutation proﬁles) may play a
role in the future as the medicines
they are linked with achieve regula-
tory approval.
I/D 83%
ctDNA assessment is not ready for rou-
tine clinical practice use and is not
recommended, either for demon-
stration of PD or selection of tar-
geted therapies.
I/D 74%
In case an ABC patient was tested in
the context of a clinical trial and the
information is available:
 If an ABC patient presents with a
tumour withMSI-H/MMR deﬁ-
ciency, treatment with an anti-PD-1
agent is a possible consideration.
 If an ABC patient presents with a
tumour with an NTRK fusion,
treatment with a TRKi is a possible
consideration.
Expert opinion/
C
Yes: 41%
Abstain: 10%
Insufﬁcient
data: 49%
Expert opinion/
C
Yes: 29%
Abstain: 24%
Insufﬁcient
data: 47%
Patients must be informed about
the amount of data available for ABC
speciﬁcally. Research on the best
companion diagnosis tools and
techniques is needed. Prospective
registries should be created to col-
lect data from all patients treated
with these innovative approaches,
after proper consent.
Continued
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Next-generation sequencing (NGS) assesses mutations and copy
number changes in many genes in the same assay. Multigene
sequencing is now available widely by companies and in many
institutions.
Multigene sequencing assesses four different sets of alterations.
First, it can detect level I/II alterations, i.e. a few alterations for
which targeted therapies provide clinical benefit (level I) or ob-
jective responses (level II). In breast cancer, there are five somatic
genomic alterations that have been associated with objective re-
sponse in phase I/II trials. These are PIK3CA, AKT1, ERBB2,
ESR1 mutations and NTRK fusions. There is not yet evidence
from prospective randomised trials that targeting these altera-
tions improves survival. Second, multigene panels can detect gen-
omic alterations associated with drug sensitivity in pre-clinical
models, but for which clinical evidence of actionability is lacking
(level III). In breast cancers there are 15–20 level III genomic
alterations, including genomic alterations on TP53, MAP2K4,
PIK3R1, SF3B1, ATM, ATR, NOTCH etc. alterations. Third, mul-
tigene panels can detect genomic alterations located on other
cancer-related genes (several hundreds), for which pre-clinical
and clinical studies are lacking (level IV). There is no evidence
that matching a therapy to these level IV alterations improves
outcome. Multigene panels can also detect mutational load, mu-
tational processes and genomic score, including mismatch repair
(MMR) deficiency and microsatellite instability (MSI). There is
evidence that MSI can be used to match patients to immune
checkpoint inhibitors. There is currently no evidence from pro-
spective clinical trials (e.g. SAFIR and SHIVA trials) that
using a multigene panel improves outcome of patients [54, 55].
The current potential value of using multigene panels is only to
steer patients to clinical trials exploring the efficacy of PI3K, AKT,
HER2, NTRK inhibitors or selective oestrogen receptor degraders
(SERDs). Moreover, it is important to recognise that the wide use
of multigene panels outside of a research programme could gen-
erate an increase in the use of drugs off-label despite the lack of
evidence that patients truly benefit from this practice. However,
multigene panels could be used to detect MMR/MSI if the assay
includes the relevant markers, and direct patients toward the use
of pembrolizumab in the USA.
It is important to note that almost half of the panel considered
that there is insufficient data to issue guidelines regarding what to
do in the presence of an MSI-high (MSI)/MMR deficiency or
NTRK fusion. In conclusion, multigene assays should not be used
in routine clinical practice for breast cancer patients (with possible
exception of MMR/MSI in the USA only). These assays should be
used in context of molecular triage programmes where patients
are potential candidates for appropriately targeted clinical trials.
Section IX: Specific sites of metastases
Continued
Guideline statement LoE/GoR Consensus
Immunotherapy, with a checkpoint
inhibitor, for any biological subtype
of ABC should not be used in rou-
tine clinical practice, outside clinical
trials. Several ongoing trials are eval-
uating the role of this type of treat-
ment in all ABC subtypes.
III/D 85%
In green, NEW ABC 4 statements.
ABC, advanced breast cancer; Consensus, percentage of panel members
in agreement with the statement; ctDNA, circulating tumour DNA; GoR,
grade of recommendation; LoE, available level of evidence; MMR, mis-
match repair; MSI-H, microsatellite instability-high; NGS, next-generation
sequencing; NTRK, neurotrophic receptor tyrosine kinase; PD, disease
progression; PD-1, programmed death 1; TRKi, tropomyosin receptor kin-
ase inhibitor.
Guideline statement LoE/GoR Consensus
Bone metastases
Radiological assessments are required in
patients with persistent and localised
pain due to bone metastases to deter-
mine whether there are impending or
actual pathological fractures. If a fracture
of a long bone is likely or has occurred,
an orthopaedic assessment is required
as the treatment of choice may be surgi-
cal stabilisation, which is generally fol-
lowed by RT. In the absence of a clear
fracture risk, RT is the treatment of
choice.
I/A 96%
Neurological symptoms and signs which
suggest the possibility of spinal cord
compression must be investigated as a
matter of urgency. This requires a full
radiological assessment of the potentially
affected area as well as adjacent areas of
the spine. MRI is the method of choice.
An emergency surgical opinion (neuro-
surgical or orthopaedic) may be
required for surgical decompression. If
no decompression/stabilisation is feas-
ible, emergency RT is the treatment of
choice and vertebroplasty is also an
option.
I/B 100%
A bone-modifying agent (bisphospho-
nate, denosumab) should be routinely
used in combination with other system-
ic therapy in patients with ABC and
bone metastases.
I/A 95%
Three-monthly zoledronic acid seems to
be not inferior to standard monthly
schedule.
I/B 95%
Supplementation of calcium and vitamin
D3 is mandatory, unless contraindica-
tions exist.
I/A 95%
Continued
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Continued
Guideline statement LoE/GoR Consensus
Brain metastases
Patients with a single or a small number of
potentially resectable brain metastases
should be treated with surgery or radio-
surgery. Radiosurgery is also an option
for some unresectable brain metastases.
I/B 92%
If surgery/radiosurgery is carried out, it
may be followed by WBRT, but this
should be discussed in detail with the
patient, balancing the longer duration
of intracranial disease control and the
risk of neurocognitive effects.
I/C 72%
HER2-positive ABC and brain
metastases
Because patients with HER2-positive ABC
and brain metastases can live for several
years, consideration of long-term tox-
icity is important and less toxic local
therapy options (e.g. stereotactic RT)
should be preferred to WBRT, when
available and appropriate (e.g. in the set-
ting of a limited number of brain
metastases).
I/A 89%
In patients with HER2-positive ABC who
develop brain metastases with stable
extracranial disease, systemic therapy
should not be changed.
I/D 95%
For patients with HER2-positive ABC where
brain metastases are the only site of re-
currence, the addition of ChT to local
therapy is not known to alter the course
of the disease and is not recommended.
I/D 83%
It is recommended to re-start the anti-
HER2 therapy (trastuzumab) if this had
been stopped.
I/B 83%
For patients with HER2-positive ABC with
progressive brain metastases as the pre-
dominant cause of disease burden, if no
further relevant local therapy options
are available, a change in systemic ther-
apy is a reasonable option, preferably in
clinical trials.
III/A 85%
Radionecrosis after stereotactic RT for
brain metastases is an uncommon com-
plication that may occur especially with
longer survival and follow-up, and in
particular in cases of re-irradiation.
Differential diagnosis with tumour pro-
gression is often difﬁcult. Treatment of
symptomatic patients with a course of
high-dose steroids is the ﬁrst treatment
of choice. If no response, bevacizumab
may be used, as an option to decrease
III/B 61%
Continued
Continued
Guideline statement LoE/GoR Consensus
the surrounding oedema, usually at a
dose of 7.5 mg/kg every 2 weeks, for a
median of four cycles. Prospective rand-
omised trials are needed to validate fur-
ther this option.
Liver metastases
Prospective RCTs of local therapy for breast
cancer liver metastases are urgently
needed, since available evidence comes
only from series in highly selected
patients. Since there are no randomised
data supporting the effect of local ther-
apy on survival, every patient must be
informed of this when discussing a po-
tential local therapy technique. Local
therapy should only be proposed in
very selected cases of good PS, with lim-
ited liver involvement, no extrahepatic
lesions, after adequate systemic therapy
has demonstrated control of the disease.
Currently, there are no data to select the
best technique for the individual patient
(surgery, stereotactic RT, intrahepatic
ChT etc.).
Expert opinion/
C
83%
Malignant pleural effusions
Malignant pleural effusions require system-
ic treatment with/without local
management.
III/A 86%
Thoracentesis for diagnosis should be car-
ried out if it is likely that this will change
clinical management. False negative
results are common.
III/B 86%
Drainage is recommended in patients with
symptomatic, clinically signiﬁcant pleural
effusion.
III/A 86%
Use of an intrapleural catheter or intrapleu-
ral administration of talc or drugs (e.g.
bleomycin, biological response modi-
ﬁers) can be helpful.
III/B 86%
Clinical trials evaluating the best technique
are needed.
Chest wall and regional (nodal)
recurrences
Due to the high risk of concomitant distant
metastases, patients with chest wall or
regional (nodal) recurrence should
undergo full restaging, including assess-
ment of chest, abdomen and bone.
Expert opinion/
A
100%
Chest wall and regional recurrences should
be treated with surgical excision when
feasible with limited risk of morbidity.
II/A 97%
Continued
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With the development of several efficacious anti-HER2 therapies,
the survival of HER2-positive ABC patients has increased, even
after the appearance and treatment of brain metastases. For these
reasons, radionecrosis, a rare but possible medium-term compli-
cation of stereotactic radiotherapy (RT) for brain metastases may
occur. In the absence of a biopsy or surgical excision, differential
diagnosis with tumour progression is often difficult. When symp-
tomatic, treatment with a course of high-dose steroids is the first
treatment of choice. Bevacizumab has been evaluated in some
studies [56–61] with limited number of patients, as an option to
decrease the surrounding oedema, if no response is obtained with
steroids. Different doses and durations have been evaluated, usu-
ally a dose of 7.5 mg/kg every 2 weeks, for a median of four cycles.
More prospective randomised trials are needed to validate further
this option.
Section X: Specific populations
Section XI: LABC
Continued
Guideline statement LoE/GoR Consensus
Locoregional RT is indicated for patients
not previously irradiated.
II/A 97%
For patients previously irradiated, re-irradi-
ation of all or part of the chest wall may
be considered in selected cases.
Expert opinion/
C
97%
In addition to local therapy (surgery and/or
RT), in the absence of distant metasta-
ses, the use of systemic therapy (ChT, ET
and/or anti-HER2 therapy) should be
considered.
I/B 95%
ChT after ﬁrst local or regional recurrence
improves long-term outcomes primarily
in ER-negative disease and can be used.
I/B 95%
ET in this setting improves long-term out-
comes for ER-positive disease and
should be used.
I/B 95%
The choice of systemic treatment depends
on tumour biology, previous treatments,
length of DFI and patient-related factors
(comorbidities, preferences etc.).
Expert opinion/
A
95%
In patients with disease not amenable to
radical local treatment, the choice of
palliative systemic therapy should be
made according to principles previously
deﬁned for ABC. These patients may still
be considered for palliative local
therapy.
Expert opinion/
B
97%
In green, NEW ABC 4 statements.
ABC, advanced breast cancer; ChT, chemotherapy; Consensus, percent-
age of panel members in agreement with the statement; DFI, disease-
free interval; ER, oestrogen receptor; ET, endocrine therapy; GoR, grade of
recommendation; HER2, human epidermal growth factor 2; LoE, available
level of evidence; MRI, magnetic resonance imaging; PS, performance
status; RCT, randomised controlled trial; RT, radiotherapy; WBRT, whole
brain radiotherapy.
Guideline statement LoE/GoR Consensus
Advanced male breast cancer
For ER-positive male ABC, which represents
the majority of the cases, ET is the pre-
ferred option, unless there is concern or
proof of endocrine resistance or rapidly
progressive disease needing a fast
response.
III/A 100%
For ER-positive male ABC tamoxifen is the
preferred option.
IV/B 83%
For male patients with ABC who need to
receive an AI, a concomitant LHRH
agonist or orchidectomy is the preferred
option. AI monotherapy may also be
considered, with close monitoring of
response.
IV/B 86%
Clinical trials are needed in this patient
population.
No new statements for this section were developed at ABC 4.
ABC, advanced breast cancer; AI, aromatase inhibitor; Consensus, per-
centage of panel members in agreement with the statement; ER, oestro-
gen receptor; ET, endocrine therapy; GoR, grade of recommendation;
LHRH, luteinising hormone-releasing hormone; LoE, available level of
evidence.
Guideline statement LoE/GoR Consensus
Before starting any therapy, a core biopsy
providing histology and biomarker (ER,
PgR, HER2, proliferation/grade) expres-
sion is indispensable to guide treatment
decisions.
I/A 97%
Since LABC patients have a signiﬁcant risk
of metastatic disease, a full staging
work-up, including a complete history,
physical examination, laboratory tests
and imaging of chest and abdomen
(preferably with CT scan) and bone, be-
fore initiation of systemic therapy is
highly recommended.
I/A 100%
PET-CT, if available, may be used (instead
of and not in addition to CT scans and
bone scan).
II/B 100%
Systemic therapy (not surgery or RT)
should be the initial treatment.
III/A 100%
Continued
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The majority of patients who present with unresectable non-
metastatic disease should first be treated with primary systemic
therapy. If rendered resectable, this should be followed by surgery
and RT. If the disease remains unresectable, RT should be consid-
ered to treat all sites of the original tumour extension, with a
boost to residual disease. Most durable remissions can be
expected with an elective dose up to an equivalent of 50 Gy to
regions with a high likelihood of bearing subclinical disease and a
boost up to 60–76 Gy (depending on the dose to the organs at
risk) to all sites of macroscopic disease. Regular evaluation during
the course of RT is advised, to select patients that might become
amenable for resection after 45–50 Gy. Interesting reports are
published on combined RT and ChT like 5-FU, docetaxel or
vinorelbine [62]. Further evaluation of the influence of combin-
ing RT with systemic treatment using a PARP inhibitor is on-
going in a prospective trial in patients with LABC or metastatic
TNBC cancer and in non-responders to primary ChT [63].
Continued
Guideline statement LoE/GoR Consensus
If LABC remains inoperable after systemic
therapy and eventual RT, ‘palliative’
mastectomy should not be done, unless
the surgery is likely to result in an overall
improvement in QoL.
Expert opinion/
D
100%
A combined treatment modality based on
a multidisciplinary approach (systemic
therapy, surgery and RT) is strongly indi-
cated in the majority of cases.
I/A 100%
Options for HR-positive LABC include an
anthracycline- and taxane-based ChT
regimen, or ET.
I/A 85%
The choice of ChT versus ET, as initial treat-
ment, will depend on tumour (grade,
biomarker expression) and patient
(menopausal status, PS, comorbidities,
preference) considerations.
Expert opinion/
A
85%
For triple-negative LABC, anthracycline-
and taxane-based ChT is recommended
as initial treatment.
I/A 85%
For HER2-positive LABC, concurrent tax-
ane and anti-HER2 therapy is recom-
mended since it increases the rate of
pCR.
I/A 92%
For HER2-positive LABC, anthracycline-
based ChT should be incorporated in
the treatment regimen.
I/A 72%
When an anthracycline is given, it should
be administered sequentially with the
anti-HER2 therapy.
I/A 87%
For patients with HER2-positive LABC
(inﬂammatory or non-inﬂammatory),
without distant metastases, who are in
complete remission after appropriate
neoadjuvant systemic therapy and ap-
propriate locoregional therapy, and
being treated with a potential curative
intent, the approved adjuvant duration
of 1 year of anti-HER2 therapy should be
used.
I/A 85%
Following effective neoadjuvant systemic
therapy with or without RT, surgery will
be possible in many patients. This will
consist of mastectomy with axillary dis-
section in the majority of cases, but in
selected patients with a good response,
BCS may be possible.
II/A 98%
In patients with axillary low burden of dis-
ease at presentation (previously cN0-
cN1) with complete response after sys-
temic treatment (ycN0), sentinel lymph
node biopsy can be an option, provided
all the recommendations for sentinel
III/B 62%
Continued
Continued
Guideline statement LoE/GoR Consensus
node after primary systemic treatment
are followed (i.e. dual tracer, clipping/
marking positive nodes, minimum of
three sentinel nodes).
Inﬂammatory LABC
For inﬂammatory LABC, overall treatment
recommendations are similar to those
for non-inﬂammatory LABC, with sys-
temic therapy as ﬁrst treatment.
I/A 93%
Mastectomy with axillary dissection is rec-
ommended in almost all cases, even
when there is good response to primary
systemic therapy.
I/A 95%
Immediate reconstruction is generally not
recommended in patients with inﬂam-
matory LABC.
IV/E 95%
Locoregional RT (chest wall and lymph
nodes) is required, even when a pCR is
achieved with systemic therapy.
I/A 98%
In green, NEW ABC 4 statements.
aFor the purpose of these recommendations, LABC means inoper-
able, non-metastatic locally advanced breast cancer.
ABC, advanced breast cancer; BCS, breast-conserving surgery; ChT,
chemotherapy; Consensus, percentage of panel members in agreement
with the statement; CT, computed tomography; ER, oestrogen receptor;
ET, endocrine therapy; GoR, grade of recommendation; HER2, human epi-
dermal growth factor 2; HR, hormone receptor; LABC, locally advanced
breast cancer; LoE, available level of evidence; pCR, pathological com-
plete response; PET, positron emission tomography; PgR, progesterone
receptor; PS, performance status; QoL, quality of life; RT, radiotherapy.
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Section XII: Supportive and palliative care
Guideline statement LoE/GoR Consensus
Supportive care allowing safer and more
tolerable delivery of appropriate treat-
ments should always be part of the
treatment plan.
I/A 100%
Early introduction of expert palliative care,
including effective control of pain and
other symptoms, should be a priority.
I/A 100%
Access to effective pain treatment (includ-
ing morphine, which is inexpensive) is
necessary for all patients in need of pain
relief.
I/A 100%
Optimally, discussions about patient pref-
erences at the end of life should begin
early in the course of metastatic disease.
However, when active treatment no lon-
ger is able to control widespread and
life-threatening disease, and the toxic-
ities of remaining options outweigh
beneﬁts, physicians and other members
of the healthcare team should initiate
discussions with the patient (and family
members/friends, if the patient agrees)
about end-of-life care.
Expert opinion/
A
96%
Management of cancer-related fatigue
Cancer-related fatigue is frequently experi-
enced by patients with ABC, exerts a
deleterious impact on QoL and limits
physical, functional, psychological and
social well-being. The aetiology of this
fatigue is complex; therefore, effective
management needs to be
multidimensional.
– 100%
It is important to assess cancer-related fa-
tigue using appropriate PROMs before
implementing various non-pharmaco-
logical approaches, such as exercise [I,
A], and, if needed, pharmacological
interventions [II, B].
See in
statement
100%
Management of CDK inhibitor-
induced neutropaenia
Neutropaenia is the most common toxicity
associated with CDK 4/6 inhibition and
is not generally associated with febrile
neutropaenia, although an increase in
infections has been reported. Treatment
should be delayed until neutrophils
have recovered to at least 1000/lL; dose
reduction can also be considered.
II/A 100%
Continued
Continued
Guideline statement LoE/GoR Consensus
Management of non-infectious
pneumonitis
NIP is an uncommon complication of
mTOR inhibition. Patient education is
critical to ensure early reporting of re-
spiratory symptoms. Treatment interrup-
tion and dose reduction are generally
effective for grade 2 symptomatic NIP
with use of systemic steroids and
treatment discontinuation for grade 3
or greater toxicity.
II/A 100%
Management of dyspnoea
Treatable causes like pleural effusion, pul-
monary emboli, cardiac insufﬁciency, an-
aemia or drug toxicity must be ruled
out. Patient support is essential. Oxygen
is of no use in non-hypoxic patients.
– 100%
Opioids are the drugs of choice in the palli-
ation of dyspnoea.
I/A 100%
Benzodiazepines can be used in patients
experiencing anxiety.
II/A 100%
Steroids can be effective in dyspnoea
caused by lymphangitis carcinomatosis,
RT or drug-induced pneumonitis, super-
ior vena cava syndrome, an inﬂamma-
tory component or in (cancer-induced)
obstruction of the airways (in which
case laser/stent is to be considered).
Expert opinion/
B
100%
Management of nausea and vomiting
ESMO/MASCC guidelines [64] are available
for management of ChT-induced and
morphine-induced nausea and vomit-
ing, and these are endorsed by the ABC
community.
n/a 100%
There is a need to study nausea and vomit-
ing related to chronic use of anticancer
drugs.
Expert opinion/
A
100%
Management of endocrine toxicities
of mTOR inhibition
Hyperglycaemia and hyperlipidaemia are
common sub-acute complications of
mTOR inhibition. Evaluation of pre-exist-
ing diabetes or hyperglycaemia at base-
line is essential. Regular careful
monitoring of glycaemia and lipid panel
is needed to identify these toxicities.
Management of grade 1 and 2 hypergly-
caemia includes treatment with oral
antidiabetics and basal insulin, in ac-
cordance with international
II/A 100%
Continued
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As in previous editions, the ABC panel issued several recommen-
dations concerning the management of disease and treatment-
related symptoms, a problem faced daily by patients and
practicing oncologists, that can significantly affect a patient’s
QoL. At ABC 4, the recommendations for management of muco-
sitis/stomatitis have been slightly updated [reflecting the FDA ap-
proval of steroid mouthwash for stomatitis induced by
mechanistic target of rapamycin (mTOR) inhibitors] [65, 66],
and new recommendations have been made for management of
hand and foot syndrome (HFS) and ChT-induced peripheral
neuropathy (CIPN) [67–69].
When adverse events are addressed systematically and at an
early stage, they often become simple and inexpensive to treat,
allowing for a higher probability of continuation of the planned
therapy. When they get to a late stage, the adverse events become
more severe, and, as a result, management becomes more com-
plex, expensive, time-consuming and potentially less effective. As
a result, treatment modifications need to be carried out.
Prophylactic measures, early detection, diagnosis and early inter-
vention are critical. The primary objectives of adverse event man-
agement strategies are to avoid disrupting the patient’s activities
of daily living, maintain or restore patient comfort and QoL, and
Continued
Guideline statement LoE/GoR Consensus
recommendation for diabetes mellitus
treatment. Statins are indicated to treat
grade 2 and 3 hypercholesterolaemia,
and ﬁbrates should be introduced if tri-
glyceride level >500 mg/dL (with atten-
tion to possible drug–drug interaction
between everolimus and ﬁbrates).
Treatment interruption and dose reduc-
tion are generally effective for grade 2
and 3 toxicity. Treatment should be dis-
continued for grade 4 toxicity.
Management of mucositis/stomatitis
Steroid mouthwash should be used for
prevention of stomatitis induced by
mTOR inhibitors (suggested schedule:
0.5 mg/5 mL dexamethasone, 10 mL to
swish2 min, then spit out; qid).
I/B 100%
Early intervention is recommended. Expert opinion/
A
100%
For >grade 2 stomatitis, delaying treat-
ment until the toxicity resolves and con-
sidering lowering the dose of the
targeted agent are also recommended.
Expert opinion/
A
100%
Mild toothpaste and gentle hygiene are
recommended for the treatment of
stomatitis.
Expert opinion/
B
100%
Consider adding steroid dental paste to
treat developing ulcerations.
Expert opinion/
B
100%
Management of chemotherapy-
induced peripheral neuropathy
CIPN is frequent and potentially dose-limit-
ing. Risk factors for neuropathy and pre-
existing neuropathy need to be
identiﬁed.
– 100%
No medical prevention can currently be
recommended.
II/C 100%
Drug-related factors (dosing, timing, route)
can lower the risk of CIPN.
– 100%
The use of tight gloves and socks during
ChT may help reduce the incidence and
severity of CIPN.
Expert opinion/
C
100%
There are limited evidence-based treat-
ments for CIPN, with tricyclic antidepres-
sants, serotonin-noradrenaline re-uptake
inhibitors, pregabalin and gabapentin
being most often used.
II/B 100%
High-quality studies are needed to evalu-
ate strategies for prevention and man-
agement of CIPN.
– 100%
Continued
Continued
Guideline statement LoE/GoR Consensus
Management of hand and foot
syndrome
HFS is also described as palmar–plantar
erythrodysesthaesia syndrome. Most fre-
quent causes are capecitabine; pegy-
lated liposomal doxorubicin; multikinase
inhibitors.
– 100%
Patients should be instructed about early
recognition of HFS.
– 100%
Drug-related factors (dosing, timing, route)
can lower the risk of HFS.
– 100%
Treatment of hyperkeratosis/fungal infec-
tions, comfortable shoes, avoidance of
friction and heat are recommended.
Expert opinion/
A
100%
Intensive skin care of hands and feet (urea
cream/ointment) is recommended.
II/A 100%
High-quality studies are needed to evalu-
ate strategies for prevention and man-
agement of HFS.
– 100%
In green, NEW ABC 4 statements.
ABC, advanced breast cancer; CDK, cyclin-dependent kinase; ChT, chemo-
therapy; CIPN, chemotherapy-induced peripheral neuropathy; Consensus,
percentage of panel members in agreement with the statement; ESMO,
European Society for Medical Oncology; GoR, grade of recommendation;
HFS, hand and foot syndrome; LoE, available level of evidence; MASCC,
Multinational Association of Supportive Care in Cancer; mTOR, mechanis-
tic target of rapamycin; NIP, non-infectious pneumonitis; PROM, patient-
reported outcome measure; qid, four times a day; QoL, quality of life; RT,
radiotherapy.
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maintain therapy for as long as needed. In order to monitor and
recognise adverse events adequately, some key points should be
addressed: (i) educate the patient before treatment about the ad-
verse events which may appear and about prophylactic measures;
(ii) communication with the patient and their support system is
essential to avoid dose modifications and maintain QoL; tell
patients why, who, when and how they can contact their health-
care professionals; (iii) monitor the patient more frequently for
the first 12 weeks on every new treatment; from week 13 on, ac-
tively monitor every one or two cycles, depending on the treat-
ment schedule and the adverse events that may have developed;
(iv) grade adverse events accurately with an appropriate tool; (v)
treat symptoms early as this may prevent them from getting
worse; (vi) adjust management strategies based on the opinion of
the patient regarding tolerability; (vii) consider dose modifica-
tions (reductions, delays); and (viii) continue systemic treatment
whenever possible.
Section XIII: Integrative medicine
Complementary and integrative medicine (CIM) represents the
use of complementary treatments side by side with conventional
approaches in a proper therapeutic environment [70].
Alternative therapies (i.e. therapies used instead of scientifically
based medicines) are not recommended in any phase or stage of
cancer treatment. For that reason, the acronym CAM—
complementary and alternative medicine—has been replaced by
CIM excluding the alternative word from current use [70]. The
term ‘integrative oncology’ represents the application of CIM to
cancer patients. However, even in settings in which the term inte-
grative oncology has been used to refer to the combination of
complementary medicine therapies with conventional cancer
treatments the term has been defined in many different ways.
Because of this lack of consensus, it has been difficult to commu-
nicate what is meant by integrative oncology to oncologists and
other health professionals, as well as to key stakeholders such as
patients. The current definition of the term integrative oncology
is a patient-centred, evidence-informed field of cancer care that
utilises mind and body practices, natural products, and/or
Guideline statement LoE/GoR Consensus
Alternative therapies (i.e. therapies used in-
stead of scientiﬁcally-based medicines)
are not recommended in any phase or
stage of cancer treatment.
n/a/E 100%
Breast Cancer Centres/Units/Departments
should be aware that the majority of
their patients would like to be informed
about complementary and integrative
medicine and that many of them are
using it.
Expert opinion/
C
100%
Physicians should actively ask for infor-
mation about its use, in view of the
potential deleterious interactions with
speciﬁc anticancer therapies.
If complementary therapies are not avail-
able at the centre, certiﬁed contacts
should be available to promote refer-
ral to practitioners qualiﬁed in the
therapies people are interested in
receiving.
Some complementary therapies have the
potential to reduce disease symptom
burden and/or side effects of anticancer
therapies, and, therefore, improve the
QoL of ABC patients.
Expert opinion/
C
100%
Evidence suggests beneﬁcial effects of the
following methods, which can therefore
be used:
 Physical exercise/sport (equivalent to
3–5 h of moderate walking per week)
improves QoL, cardiorespiratory ﬁtness,
I/B 100%
Continued
Continued
Guideline statement LoE/GoR Consensus
physical performance and fatigue, and
it may also improve DFS and OS.
 MBSR programmes, hypnosis and yoga
may improve QoL and fatigue, and
help reduce anxiety, distress and some
side effects of anticancer therapies.
 Acupuncture may help against ChT-
induced nausea and vomiting, fatigue
and hot ﬂashes.
Methods with no or unfavourable
effects
II/E 100%
The following methods of alternative
medicine are not recommended in
ABC since available evidence shows
no effect at best, or even association
with worse outcome:
 antioxidant supplements;
 drugs outside the approved indication
(e.g. methadone);
 herbs including Chinese herbal
medicine;
 orthomolecular substances (selenium,
zinc etc.)
 oxygen and ozone therapy
 proteolytic enzymes, thymic peptides
 phytoestrogens (soy food, isoﬂavones)
 high-dose vitamins (vitamin C, D, E, car-
otenoids etc.)
 L-carnitine, laetrile.
In green, NEW ABC 4 statements.
ABC, advanced breast cancer; ChT, chemotherapy; Consensus, percent-
age of panel members in agreement with the statement; DFS, disease-
free survival; GoR, grade of recommendation; LoE, available level of evi-
dence; MBSR, mindfulness-based stress reduction; OS, overall survival;
QoL, quality of life.
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lifestyle modifications from different traditions alongside con-
ventional cancer treatments. Integrative oncology aims to opti-
mise health, QoL and clinical outcomes across the cancer care
continuum, to empower people to prevent cancer and to become
active participants before, during and beyond cancer treatment
[71].
Some complementary therapies have the potential to reduce
disease symptom burden and/or side effects of anticancer thera-
pies, and, therefore, improve the QoL of breast cancer patients.
The research and evidence of the effects of complementary treat-
ments specifically for ABC patients is very limited and applica-
tions are usually extrapolated from indications in early breast
cancer patients.
Evidence suggests beneficial effects of the following methods,
which can, therefore, be used: (i) physical exercise/sport (equiva-
lent to 3–5 hours of moderate walking per week) improves
cardiorespiratory fitness, physical performance and fatigue, and
it may also improve DFS and OS in breast cancer patients; add-
itionally, a supervised and individualised exercise results in an
improvement in functional ability and QoL functions in women
with ABC [72] [IV/B]; (ii) mindfulness-based stress reduction
(MBSR) programmes, hypnosis and yoga may improve QoL and
fatigue, improve sleep and help reduce anxiety, distress and some
side effects of anticancer therapies; and (iii) acupuncture may
help against ChT-induced nausea and vomiting, fatigue and hot
flashes [70, 73].
Evidence suggests that the following complementary therapies
should not be recommended in ABC patients since available evi-
dence shows no effect at best, or even association with worse out-
come: (i) antioxidant supplements; (ii) drugs outside the
approved indication (e.g. methadone); (iii) herbs including
Chinese herbal medicine; (iv) orthomolecular substances (selen-
ium, zinc etc.); (v) oxygen and ozone therapy; (vi) proteolytic
enzymes, thymic peptides; phytoestrogens (soy food, isofla-
vones); (vii) high-dose vitamins (vitamin C, D, E, carotenoids,
L-carnitine, laetrile etc.) [70, 73].
Discussion
Conclusions and future directions
To facilitate the use of these guidelines in clinical practice, all
statements have been organised by subject, highlighting those
who were recently developed at ABC 4. A new, ESMO-adapted
LoE/GoR system was introduced and, when indicated, the
ESMO-MCBS was applied and v1.1 scores were added. Should
another agent be approved by EMA before the next ABC
Consensus Conference, ESMO will apply the ESMO-MCBS and
the result will be made available as an eUpdate to the present
guidelines.
To address some of the needs highlighted by the ABC guide-
lines, two projects are ongoing: the development of HRQoL tools
specific for ABC patients (a collaboration between the EORTC
Quality of Life and Breast Cancer Groups), and the development
of quality indicators for ABC, which will in the future be included
in the certification process of breast units/centres/services. The
latter project is a collaboration between EUSOMA and ESO,
under the umbrella of the ABC Global Alliance (https://www.abc
globalalliance.org).
Efforts must continue not only in research dedicated to ABC,
but also ensuring that ABC patients worldwide have access to the
best available therapies, including multidisciplinary care as well
as early and adequate access to supportive and palliative care.
Reimbursement rules in all countries should be patient-centred
and be an incentive, not work against, the clinical implementa-
tion of high-quality international guidelines. Only united and
with common projects and goals, the ABC community will be
able to achieve success. This was the main objective of the cre-
ation of the ABC Global Alliance, which is a multi-stakeholder
platform for all those (advocacy groups, pharma, cooperative
groups, societies, individuals) interested in collaborating in com-
mon projects relating to ABC around the world and is a continu-
ation of the work developed through the ABC International
Consensus Conference and Guidelines. Its mission and vision are
to improve and extend the lives of women and men living with
ABC in all countries worldwide, to fight for a cure for ABC, to
raise awareness of ABC and to lobby worldwide for improvement
in the lives of ABC patients. As a first step, the Global Alliance has
developed an ABC Global Charter, defining 10 achievable and
measurable goals for a period of 10 years (till 2025) [74]. These
goals include doubling the median survival of patients by 2025,
improving QoL in clinical practice, increasing availability and ac-
cess to multidisciplinary care, offering communication skills
training, improving availability of robust epidemiology and out-
comes data, improving access to non-clinical supportive services,
protecting workforce rights for ABC patients and increasing pub-
lic understanding about ABC to fight the still existent stigma.
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